Bioray Biotech Co (ROCO:7561) Debt-to-Equity : 0.22 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Bioray Biotech Co Debt-to-Equity?

Bioray Biotech Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$44.7 Mil. Bioray Biotech Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$46.1 Mil. Bioray Biotech Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was NT$417.0 Mil. Bioray Biotech Co's debt to equity for the quarter that ended in Jun. 2024 was 0.22.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bioray Biotech Co's Debt-to-Equity or its related term are showing as below:

ROCO:7561' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.16 Max: 0.22
Current: 0.22

During the past 7 years, the highest Debt-to-Equity Ratio of Bioray Biotech Co was 0.22. The lowest was 0.04. And the median was 0.16.

ROCO:7561's Debt-to-Equity is ranked better than
57.33% of 839 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs ROCO:7561: 0.22

Bioray Biotech Co Debt-to-Equity Historical Data

The historical data trend for Bioray Biotech Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioray Biotech Co Debt-to-Equity Chart

Bioray Biotech Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.17

0.15

0.22

0.16

Bioray Biotech Co Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial								0.16	0.22	0.19	0.16	0.22

Competitive Comparison of Bioray Biotech Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioray Biotech Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bioray Biotech Co's Debt-to-Equity falls into.

Bioray Biotech Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bioray Biotech Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.137	+	65.655)	/	433.896
	=	0.16

Bioray Biotech Co's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(44.689	+	46.069)	/	416.965
	=	0.22

Bioray Biotech Co (ROCO:7561) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bioray Biotech Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bioray Biotech Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioray Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioray Biotech Co Ltd (ROCO:7561) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 21-3, Shennong East Road, Changzhi Township, Pingtung County, Pingtung City, TWN, 90846

Website

http://www.bio-ray.com.tw

Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations. The company provides capsules, powders, lozenges, and liquids for Skincare, Anti-aging and anti-inflammatory, Silver Hair Maintenance, and Microbe and mineral supplement among others.

Bioray Biotech Co Headlines

No Headlines